Skip to Content
Merck
CN

Key Documents

View All Documentation

C-060

Cyclobenzaprine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C20H22ClN
CAS Number:
6202-23-9
Molecular Weight:
311.85
UNSPSC Code:
41116107
MDL number:
MFCD00079039
NACRES:
NA.24
EC Number:
200-659-6
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Cl.CN(C)CC\C=C1\c2ccccc2C=Cc3ccccc13

InChI

1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H

InChI key

VXEAYBOGHINOKW-UHFFFAOYSA-N

Gene Information

human ... HTR2A(3356), HTR2C(3358)

Related Categories

General description

Cyclobenzaprine is a muscle relaxant sold under the trade name Flexeril® to relieve skeletal muscle spasms and associated pain from acute musculoskeletal conditions. This Snap-N-Spike® Reference Solution is suitable for use in LC/MS or GC/MS methods for clinical toxicology, forensic analysis, or urine drug testing applications.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Flexeril is a registered trademark of ALZA Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Mestres et al.
Clinical pharmacology and therapeutics, 90(5), 662-665 (2011-10-07)
The link between cyclobenzaprine (Flexeril) administration and serotonin syndrome (SS) is subject to debate. Establishing such a connection is difficult because of the limited number of case reports available and the almost complete ignorance of its preclinical pharmacology. In this
Reinhard Reuss et al.
Pharmacology, 84(2), 91-92 (2009-07-11)
The muscle-relaxing 5-HT(2) receptor antagonist cyclobenzaprine is structurally closely related to amitriptyline. It is widely used to treat patients presenting with back pain and fibromyalgia. Very rarely cyclobenzaprine toxicity can result in extrapyramidal symptoms, but occurrence of torticollis has not
D R Abernethy et al.
Clinical pharmacology and therapeutics, 90(5), 645-646 (2011-10-21)
The rapid evolution of large biological, pharmacological, and chemical databases has led to optimism that such data resources can be leveraged for prediction of drug action based on molecular descriptors of the drug. Challenges to realize this possibility include organization
Sleep as a window into the world of fibromyalgia syndrome.
Robert Joseph Thomas
The Journal of rheumatology, 38(12), 2499-2500 (2011-12-03)
José Luiz Pedroso et al.
Arquivos de neuro-psiquiatria, 69(2B), 288-291 (2011-06-01)
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disorder characterized by late-infantile onset spastic ataxia and other neurological features. ARSACS has a high prevalence in northeastern Quebec, Canada. Several ARSACS cases have been reported outside Canada in recent
View All Related Papers

Global Trade Item Number

SKUGTIN
C-060-1ML04061833444610
44613-100ML04061832284507

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service